Title : Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice.

Pub. Date : 2022 Jan

PMID : 34894319






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice. osimertinib epidermal growth factor receptor Homo sapiens